Antitumor effects of a recombinant pseudotype baculovirus expressing Apoptin in vitro and in vivo

Yongfei Pan1, Liurong Fang, Huiying Fan

  • 1Division of Animal Infectious Diseases, State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People's Republic of China.

Insights

Apoptin, a novel protein, effectively triggers cancer cell death independently of p53. When delivered via a pseudotype baculovirus vector, Apoptin demonstrated significant tumor suppression and improved survival in preclinical models, highlighting its potential in cancer gene therapy.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Apoptin, derived from chicken anemia virus, induces apoptosis in tumor cells independent of p53 and Bcl-2.
  • Gene therapy offers a promising avenue for cancer treatment, requiring efficient and specific delivery vectors.

Purpose of the Study:

  • To evaluate the efficacy of Apoptin delivered by a pseudotype baculovirus vector for cancer treatment.
  • To assess the in vitro and in vivo anti-tumor activity of the recombinant baculovirus expressing Apoptin.

Main Methods:

  • Construction of a recombinant pseudotype baculovirus (BV-Apoptin) expressing Apoptin.
  • In vitro apoptosis induction assays in HepG2 and H22 cancer cell lines.
  • In vivo studies involving intratumoral injection of BV-Apoptin in a xenogeneic mouse tumor model.

Main Results:

  • BV-Apoptin efficiently expressed Apoptin and induced apoptosis in cancer cells.
  • Intratumoral injection of BV-Apoptin significantly suppressed tumor growth in mice.
  • Treatment with BV-Apoptin significantly prolonged the survival of tumor-bearing mice compared to control.

Conclusions:

  • Apoptin delivered via pseudotype baculovirus exhibits potent anti-tumor activity.
  • BV-Apoptin demonstrates potential as a therapeutic agent for solid tumors.
  • This study supports the development of Apoptin-based gene therapy for cancer treatment.